QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sprague, D. A Articles by Raymond, C. B Search for Related Content PubMed PubMed Citation Articles by Sprague, D. A Articles by Raymond, C. B

DRUG SELECTION PERSPECTIVES

Selection of Atypical Antipsychotics for the Management of Schizophrenia

Clinical Pharmacist, Pharmaceutical Sciences Clinical Service Unit, Vancouver Hospital & Health Sciences Centre, Vancouver, British Columbia, Canada

Peter S Loewen, PharmD

Pharmacotherapeutic Specialist—Internal Medicine, Pharmaceutical Sciences Clinical Service Unit, Vancouver Hospital & Health Sciences Centre; Clinical Assistant Professor of Pharmacy, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver

Colette B Raymond, PharmD

at time of writing, Pharmacotherapeutic Specialist—Psychiatry, Pharmaceutical Sciences Clinical Service Unit, Vancouver Hospital & Health Sciences Centre; Clinical Assistant Professor of Pharmacy, Faculty of Pharmaceutical Sciences, University of British Columbia; now, Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada

Reprints: Denise A Sprague BSc(Pharm), CSU–Pharmaceutical Sciences, UBC Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 2B5, Canada, fax 604/822-9742, dsprague{at}vanhosp.bc.ca

OBJECTIVE: To review the evidence for selecting one atypical antipsychotic agent over another for management of schizophrenia.

DATA SOURCES: A literature search of MEDLINE (1966–June 2003), EMBASE (1998–June 2003), and the Cochrane Library was conducted using the following terms: schizophrenia, quetiapine, ziprasidone, olanzapine, aripiprazole, and risperidone. Bibliographies of relevant articles were hand-searched for additional references.

STUDY SELECTION AND DATA EXTRACTION: Prospective, randomized, blinded trials and meta-analyses that directly or indirectly compared 2 atypical antipsychotic agents in the management of schizophrenia are included in this review. Studies comparing an atypical agent with clozapine are not included.

DATA SYNTHESIS: A small number of prospective, randomized, blinded trials that compare efficacy and tolerability of olanzapine and risperidone have been published. These trials did not reveal clinically meaningful differences in efficacy but did confirm that their adverse effect profiles are slightly different (more weight gain with olanzapine and more extrapyramidal reactions with risperidone). Direct comparisons between other atypical antipsychotics are not available. Systematic reviews (indirect comparisons) of placebo-controlled or traditional antipsychotic-controlled trials suggest similar efficacy for quetiapine, olanzapine, and risperidone when placebo is the comparator and inferior efficacy of quetiapine compared to olanzapine and risperidone when haloperidol is the comparator. The few available economic analyses are difficult to interpret in light of current practice.

CONCLUSIONS: Additional randomized, blinded clinical trials directly comparing efficacy, tolerability, and cost-effectiveness are needed to confirm the proposed differences among atypical antipsychotic agents before recommendations can be made with confidence.

Key Words: antipsychotics, schizophrenia

Published Online, December 30, 2003. www.theannals.com, DOI 10.1345/aph.1C461

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-04-008-H01

This article has been cited by other articles:

				R. Ohlsen, R. Williamson, B. Yusufi, J. Mullan, D. Irving, S. Mukherjee, E. Page, K. Aitchison, and T. Barnes Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine J Psychopharmacol, May 1, 2008; 22(3): 323 - 329. [Abstract] [PDF]

				J. M. Noel ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 863 - 876. [Full Text] [PDF]

				T. L Bettinger, G. Shuler, D. R Jones, and J. P Wilson Schizophrenia: Multi-Attribute Utility Theory Approach to Selection of Atypical Antipsychotics Ann. Pharmacother., February 1, 2007; 41(2): 201 - 207. [Abstract] [Full Text] [PDF]

				S. Gentile Clinical Utilization of Atypical Antipsychotics in Pregnancy and Lactation Ann. Pharmacother., July 1, 2004; 38(7): 1265 - 1271. [Abstract] [Full Text] [PDF]